Gilead to buy Arcellx in nearly $8B deal | STAT – statnews.com

Gilead Sciences is buying Arcellx in a deal worth $7.8 billion, picking up its partner on a CAR-T therapy for multiple myeloma.

#stockmarket #breaking

Leave a Reply

WP Twitter Auto Publish Powered By : XYZScripts.com